Adamis pharmaceuticals' clinical study assessing tempol for the treatment of covid-19 surpasses enrollment expectations

Ad-hoc dsmb meeting evaluates interim clinical and safety data and clears phase 2/3 study to continue ad-hoc dsmb meeting evaluates interim clinical and safety data and clears phase 2/3 study to continue

ADMP Ratings Summary

ADMP Quant Ranking